Intra-articular supplementation with recombinant human GDF5 arrests disease progression and stimulates cartilage regeneration in the rat medial meniscus transection (MMT) model of osteoarthritis  by Byers, B.A. et al.
Figure 1) Representative micrographs of the medial tibial plateau (bot-
tom) and medial femoral condyle (top) from study # 3. 50X original
magniﬁcation
Figure 2) Quantitation of the effects of rhGDF5 intra-articular therapy on
signiﬁcant cartilage lesion width of the medial tibial plateau. Day 21
untreated group indicates the extent of cartilage erosion present at the
onset of therapy. Data represent 15 rats/group from study # 3.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S471were revealed to be more predictive of a patient receiving TKA than the
other scores. Osteophyte, at least in patients with end-stage knee OA,
may induce disability of daily living, associating the determination of
the patients for receiving TKA. In conclusion, when we evaluate the
structural changes due to knee OA by MRI, osteophytes score is only a
predictor for receiving TKA.
861
THE RESULTS OF MODIFIED DISTRACTION ARTHROPLASTY FOR
DEGENERATED OSTEOARTHRITIS OF THE ANKLE
N. Usami V y,z, H. Ikezawa z. yUsami Orthopedic Clinic for Foot, AnZkle and
Shoe Disorders, Tokyo, Japan; zDept. of Orthpedic Surgery, Keio Univ.,
Tokyo, Japan
Purpose: In the treatment of degenerated osteoarthritis of the ankle,
we obtained good results in terms of preserving the joint functions and
relieving pain by performing a procedure to reconstruct the anatomical
structure of the ankle, accompanied by ROM exercises undertaken with
the joint space kept pulled apart with a conventionally used external
ﬁxator.
Methods: A total of 43 patients (45 ankles; 28 ankles in 28 male
patients and 17 ankles in 15 female patients) who underwent the
procedure from 1998 to 2012 were enrolled in the study. The patients
were 18-72 years old, with a mean age of 56 years at the time of the
procedure. In regard toTakakura’s classiﬁcation, 6 ankles were classiﬁed
as Stage 2, 21 as Stage 3a, 12 as Stage 3b, and 6 as Stage 4. The patients
underwent debridement by the conventional method, including
removal of bone spurs and synovectomy, combined with low tibial
osteotomy, osteochondral graft, drilling and/or reconstruction of ankle
lateral ligaments. As post-treatment, patients were started on active
ROM exercises from the day after the surgery and started partial weight
bearing at 6-8 weeks after the surgery. The external ﬁxation device was
removed to allow total weight bearing at 3 months. Follow-ups were
performed for 1-8 years, with a mean of 4 years and 7 months.
Results: The pain severity did not change in 2 ankles. For the remaining
43 ankles in which the pain improved, no problems in daily life activ-
ities, but inability to undertake sports activities were observed for 31
ankles, while no problems in either physical work or sporting activities
for 12 ankles. None of the patients took painkiller. Improvements of the
ROMwere seen in 10 ankles, while no change of the ROMwas observed
in the remaining 35 ankles. There were no patients who needed addi-
tional operations such as arthrodesis during the follow-up period.
Conclusions: Procedures such as arthrodesis, total ankle replacement
and low tibial osteotomy are performed to treat degenerated osteo-
arthritis of the ankle, but each of these is associated with problems,
including those related to the qualifying age, durability, and range of
motion. It is difﬁcult to select a proper treatment option, especially for
relatively young patients. In contrast, there is no age requirement for
the procedure described in this study, because joint functions are pre-
served by restoring the patients’ own tissue and the patients suffered
only mild postoperative limitation of the ADL. As demerits, this pro-
cedure is less effective for pain relief than arthrodesis and more
abundant experience is required, because several kinds of surgical
procedures have to be performed. However, it can be indicated for
young patients in whom preservation of the joint functions and higher
activity potential are required. In addition it is well applicable to
degenerated osteoarthritis of the ankle that arises at a relatively early
age, because future joint replacement or arthrodesis will not be difﬁcult
in patients who undergo this procedure.
Therapy- Intraarticular
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INTRA-ARTICULAR SUPPLEMENTATION WITH RECOMBINANT
HUMAN GDF5 ARRESTS DISEASE PROGRESSION AND STIMULATES
CARTILAGE REGENERATION IN THE RAT MEDIAL MENISCUS
TRANSECTION (MMT) MODEL OF OSTEOARTHRITIS
B.A. Byers y, W.R. Parrish y, J. Geesin z, U. Herzberg z, S. Wadsworth z,
A.M. Bendele x, B.J. Story y. yDePuy Synthes Mitek Sports Med., Raynham,
MA, USA; zAdvanced Therapeutics and Regenerative Med., Somerville, NJ,
USA; xBolder BioPATH, Boulder, CO, USA
Purpose: Genome-wide association studies and investigation of
osteoarthritis (OA) risk alleles suggest that reduced levels of functional
Growth and Differentiation Factor 5 (GDF5) expression in tissues of the
joint may be a precipitating factor contributing to OA. Therefore, wehypothesized that supplementation of rhGDF5 to the OA joint via intra-
articular injection may represent a viable therapeutic approach.
Methods: We used a rat medial meniscus transection (MMT) model of
OAwhich causes rapid and progressive OA-like pathology including the
aggressive erosion of articular cartilage. Three studies were conducted
(n ¼ 15 / treatment group) to investigate the feasibility of rhGDF5 in
either a preventative or therapeutic modality: (1) 6 weekly injections
beginning on day 3 post MMT with termination on day 42 (pre-
ventative), (2) 6 weekly or 3 bi-weekly injections beginning on day 21
post MMT with termination on day 63 (therapeutic), and 3) a single
injection, or a series of 2 or 3 bi-weekly injections, beginning on day 21,
with termination on day 63 (therapeutic). rhGDF5 doses ranging from
0.3 to 100 mg were studied, using a glycine buffered trehalose vehicle
(pH¼3.0). Joints were harvested and processed for histological analysis
following toluidine blue staining. Quantitative and semi-quantitative
histopathological end points were used to evaluate the extent of OA
progression in the medial tibial plateau cartilage.
Results: rhGDF5 demonstrated signiﬁcant dose-dependent cartilage
protection as a preventative therapy (Study 1). In particular, the width
of signiﬁcant tibial lesions was reduced by 11% by repeat treatment with
0.3 mg rhGDF5, 22% by 3 mg, 32% by 10 mg, and 49% by 30 mg injections
when compared with vehicle controls. Study 2 demonstrated dose-
dependent efﬁcacy of rhGDF5 compared with vehicle controls when
administered in a therapeutic modality beginning on day 21 post MMT.
Following 6 weekly injections, the width of signiﬁcant tibial lesions was
reduced by 30% by a 10 mg rhGDF5 dose and by 47% by a 30 mg dose.
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reduction in thewidth of signiﬁcant tibial lesions, respectively, for 10 mg
and 30 mg doses. This partial loss in efﬁcacy by conducting 3 bi-weekly
treatments rather than 6 weekly treatments was partially compensated
for by increasing the 3 injection regimen rhGDF5 dose from 30 mg to 100
mg, which reduced lesion width by 41%. In Study 3, a single rhGDF5
injection on day 21 reduced the width of signiﬁcant tibial lesions
compared with vehicle controls by 13% and 19% for a 30 mg and 100 mg
dose respectively. The 2 injection regimen administered on days 21 and
35 post MMT reduced tibial lesion width by 18% and 28%, and the 3
injection regimen reduced these lesions by 27% and 43%. After
accounting for a modest vehicle effect, the level of Day 63 cartilage
degeneration observed with 3 biweekly injections of rhGDF5 (30 or 100
mg) was signiﬁcantly less than the untreated controls at day 21. This is
indicative of disease arrest and cartilage regeneration with repeated
injections of higher doses of rhGDF5.
Conclusions: Intra-articular delivery of rhGDF5 signiﬁcantly protected
the knee joint from MMT-induced OA disease in a dose and admin-
istration regimen dependent manner. Our data indicate that even a
single injection of 100 mg rhGDF5 has signiﬁcant therapeutic beneﬁt.
Additionally, rhGDF5 is able to arrest disease progression in a ther-
apeutic modality with as few as 2 bi-weekly injections. Moreover, 3 bi-
weekly injections of 100 mg rhGDF5 was able to stimulate cartilage
regeneration in the MMT model. Collectively, these results clearly
demonstrate the potential of rhGDF5 supplementation as a targeted
therapeutic approach for treating OA.
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MAGNETIC RESONANCE IMAGING STRUCTURAL PARAMETERS DO
NOT PREDICT RESPONSE TO INTRA-ARTICULAR STEROID THERAPY
IN KNEE OA
N. Maricar y, M.J. Parkes y, D.T. Felson y,z, T.F. Cootes y, A.D. Gait y,
E.J. Marjanovic y, D. Bailey x, C.E. Hutchinson x, T.W. O’Neill y. y The Univ. of
Manchester, Manchester, United Kingdom; zBoston Univ., Boston, MA,
USA; x The Univ. of Warwick, Coventry, United Kingdom
Purpose: Intra-articular steroid therapy is widely used in the man-
agement of osteoarthritis (OA) of the knee. Meta-analyses suggest
treatment is linked with a signiﬁcant reduction in pain at least in the
short term (< 3weeks). Steroids havemarked anti-inﬂammatory effects
and it is thought that their analgesic effect may be related in part to
this.Some knees with OA have little if any synovitis whereas in others,
synovitis, assessed as synovial volume, is similar to rheumatoid
arthritis. It is not known, however, whether response to therapy is
inﬂuenced by the degree of synovitis present nor of the presence of
bonemarrow lesions (BMLs), lesions also related to pain. The aim of this
analysis was to determine the inﬂuence of synovitis, as assessed by
synovial volume using magnetic resonance imaging (MRI), and also the
summed score of BMLs, on the symptomatic response to treatment with
intra-articular steroid therapy.
Methods: Men and women aged 40 years and older with painful knee
OA who met the American College of Rheumatology (ACR) criteria for
the disease, were recruited for participation in an ongoing open label
clinical trial of intra-articular steroid therapy. Subjects who took part in
the study had signiﬁcant knee pain and knee OA (Kellgren-Lawrence
grade 2 or more). At baseline they completed questionnaires about their
symptoms including the Knee Injury and Osteoarthritis Outcome Score
(KOOS) (0-100) with the lower scores indicating greater pain and also a
VAS (0-10) for pain during a nominated activity (VASnA) with higher
scores indicating greater pain. They subsequently had a gadoli-
nium(Gd)-enhanced MRI scan immediately prior to having an intra-
articular steroid injection (depomedrone 80 mg) with repeat ques-
tionnaires and Gd-enhanced MRI scan at follow-up visit usually within
a 2 week period. To assess synovial tissue volume, sagittal (T1W Fat
Suppressed images: TR 500ms, TE 17ms; FoV 15.9 x 15.9cm; slice
thickness 3mm) scans were obtained. Manual segmentation of the
synovial tissue layer was performed on the post-contrast knee image by
a single observer. Using computer image analysis we excluded cartilage
within the segmented space, by thresholding in the associated sagittal
(3D WATSc: TR 20ms, TE 7.7ms, FoV 15cm, 288x288) scan. The rest of
the segmented space is assumed to be a mixture of ﬂuid and synovial
tissue. We calculated the proportion of synovial tissue in every voxel
and summarized these across voxels to compute a volume of synovium.
BMLs were assessed semi-quantitatively by an experienced MSK radi-
ologist using the WORMS method (range of possible scores 0-45) andthis represented the BML score. In the analysis we looked whether the
baseline structural parameters were associated with a change in both
KOOS-pain and also VASnA.
Results: We studied 100 participants of mean age 62.0 years (SD 10.4
years) and of whom 48were female. Themedian time between baseline
and follow-up scan was 8 days (IQR 7 to 14 days). The mean synovial
tissue volume at baseline was 10,033mm3 (SD 6,495mm3), and mean
total BML score 8 (SD 5.0). Overall, pain signiﬁcantly improved fol-
lowing steroid injection as indicated by an increase in KOOS (mean
change at follow-up ¼ 22.2 points; 95% CI 18.0 to 26.4; p < 0.001) and a
reduction in VASnA (mean change at follow-up ¼ -3.1cm; 95% CI -3.7
cm to -2.5 cm; p< 0.001). Neither synovial volume (r¼ 0.026; p¼ 0.80)
nor BML score at baseline (r ¼ -0.037; p ¼ 0.72) were associated with
the observed change in KOOS-pain. Similarly neither synovial volume (r
¼ 0.064; p ¼ 0.55) nor BML score at baseline (r ¼ 0.098; p ¼ 0.37) were
associated with a change in VASnA. Overall, based on the OARSI criteria
there were 67 responders and 33 non-responders. Baseline synovial
tissue volume did not differ in those who did, compared to those who
did not, subsequently respond (mean difference ¼ -76mm3; 95% CI
-2831mm3 to 2679mm3; p ¼ 0.96). Similarly, BML score did not differ
between those who subsequently did, compared to those who did not,
respond (mean difference ¼ -0.41; 95% CI -2.53 to 1.71; p ¼ 0.70).
Conclusions: Neither synovitis nor BML score predict response to intra-
articular steroid injection in patients with symptomatic knee OA.
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ELECTROSTATIC INTERACTIONS ENABLE RAPID PENETRATION,
ENHANCED UPTAKE & RETENTION OF INTRA-ARTICULAR INJECTED
AVIDIN IN RAT KNEE JOINTS
A.G. Bajpayee y, A.M. Scheu z, R.M. Porter z, A.J. Grodzinsky y. yMIT,
Cambridge, MA, USA; zBIDMC, Harvard Med. Sch., Boston, MA, USA
Purpose: Osteoarthritis affects individual joints necessitating the need
for local therapy. Intra-articular (i.a.) injection of drugs remains inad-
equate due to rapid drug clearance from joint space. Local delivery into
cartilage is further complicated by its complex architecture of dense
